{"generic":"Antihemophilic Factor (Recombinant) Porcine Sequence","drugs":["Antihemophilic Factor (Recombinant) Porcine Sequence","Obizur"],"mono":{"0":{"id":"jyl2s0","title":"Generic Names","mono":"Antihemophilic Factor (Recombinant) Porcine Sequence"},"1":{"id":"jyl2s1","title":"Dosing and Indications","sub":{"0":{"id":"jyl2s1b4","title":"Adult Dosing","mono":"<ul><li><b>Acquired factor VIII deficiency disease - Bleeding:<\/b> Mild and moderate hemorrhage: Initial, 200 units per kg IV (rate, 1 to 2 mL\/min) every 4 to 12 hours; base subsequent dosage on factor VIII trough levels and clinical response; required factor VIII level, 50 to 100 units\/dL or 50% to 100% of normal; do not exceed factor VIII plasma levels 200% of normal or 200 units per dL<\/li><li><b>Acquired factor VIII deficiency disease - Bleeding:<\/b> Major hemorrhage: Initial, 200 units per kg IV (rate, 1 to 2 mL\/min) every 4 to 12 hours; base subsequent dosage on factor VIII trough levels and clinical response; required factor VIII level, 100 to 200 units\/dL or 100% to 200% of normal to treat acute bleed, followed by 50 to 100 units\/dL or 50% to 100% of normal once acute bleed is controlled and if required; do not exceed factor VIII plasma levels 200% of normal or 200 units per dL<\/li><\/ul>"},"1":{"id":"jyl2s1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},"3":{"id":"jyl2s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acquired factor VIII deficiency disease - Bleeding<br\/>"}}},"3":{"id":"jyl2s3","title":"Contraindications\/Warnings","sub":[{"id":"jyl2s3b9","title":"Contraindications","mono":"history of life-threatening hypersensitivity reactions to antihemophilic factor (recombinant) porcine sequence or its components, including hamster protein <br\/>"},{"id":"jyl2s3b10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- hypersensitivity reactions may occur, possibly progressing to anaphylaxis; discontinue immediately if allergic or anaphylactic-type reactions occur<\/li><li>-- development of inhibitory antibodies to antihemophilic factor have been reported; monitoring recommended<\/li><\/ul>"},{"id":"jyl2s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jyl2s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jyl2s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Immunologic:<\/b>Antibody development (26%)<br\/><b>Serious<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction<br\/>"},"6":{"id":"jyl2s6","title":"Drug Name Info","sub":{"0":{"id":"jyl2s6b17","title":"US Trade Names","mono":"Obizur<br\/>"},"2":{"id":"jyl2s6b19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"jyl2s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jyl2s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jyl2s7","title":"Mechanism Of Action","mono":"Antihemophilic factor (recombinant) porcine sequence provides temporary replacement of inhibited endogenous factor VIII in patients with acquired hemophilia A.<br\/>"},"9":{"id":"jyl2s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Recombinant porcine factor VIII potency in units is stated on each vial<\/li><li>Vials must be reconstituted prior to use; bring vial and prefilled diluent syringe to room temperature prior to reconstitution<\/li><li>Peel back cover of vial adapter package but leave adapter in plastic package<\/li><li>Remove plastic package from vial adapter to expose the filter spike<\/li><li>Firmly push filter spike through center of rubber circle on vial until clear plastic cap connects to vial<\/li><li>Push plunger down gently to inject all of diluent from syringe into vial<\/li><li>Swirl vial gently to mix, leaving syringe in place<\/li><li>Use reconstituted product within 3 hours when stored at room temperature<\/li><li>If more than one vial is required, reconstitute each using instructions above<\/li><li>Do not administer with other infusion medications using same tubing or container<\/li><li>Connect large syringe to Luer lock of vial adapter; turn clockwise until syringe is secure<\/li><li>Withdraw reconstituted antihemophilic factor (recombinant) porcine sequence into syringe<\/li><li>Repeat above process with all prepared vials to reach volume needed for administration<\/li><li>Administer IV at rate of 1 to 2 mL per minute<\/li><\/ul>"},"10":{"id":"jyl2s10","title":"Monitoring","mono":"<ul><li>control or reduction in bleeding indicates efficacy<\/li><li>1-stage clotting assay to confirm adequate plasma VIII levels, 30 minutes and 3 hours after initial dose, then 30 minutes after subsequent doses.<\/li><li>plasma factor VIII levels for adequate response, especially with life-threatening bleeding or major surgery<\/li><li>plasma factor VIII inhibitor (neutralizing antibodies) levels; if inadequate response to appropriate doses<\/li><li>aPTT normalization should not be used as an efficacy measurement<\/li><li>clinical signs of factor VIII inhibitor formation<\/li><\/ul>"},"11":{"id":"jyl2s11","title":"How Supplied","mono":"<b>Obizur<\/b><br\/>Intravenous Powder for Solution: 1 U<br\/>"},"13":{"id":"jyl2s13","title":"Clinical Teaching","mono":"Advise patient to report a hypersensitivity reaction.<br\/>"}}}